Allergolan (Gel, Drops) Instructions for Use
ATC Code
D04AA13 (Dimetindene)
Active Substance
Dimetindene (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Histamine H1-receptor blocker. Antiallergic drug
Pharmacotherapeutic Group
Antiallergic agent – H1-histamine receptor blocker
Pharmacological Action
Histamine H1-receptor blocker, an alkylamine derivative. It has antiallergic, antipruritic, and a slight anticholinergic effect. It also has a pronounced local anesthetic effect. It causes a weakly expressed sedative effect of central origin.
Pharmacokinetics
It is raply and sufficiently completely absorbed after oral administration. Bioavailability is about 70%. Plasma protein binding is 90%. It penetrates well into tissues and passes through the blood-brain barrier. It is metabolized in the liver by hydroxylation and methoxylation. It is excreted in bile and urine ( 90% as a metabolite and 10% unchanged).
With topical application, Dimetindene rapidly penetrates the skin; systemic bioavailability is 10%.
Indications
For oral administration: urticaria, hay fever, vasomotor rhinitis, food and drug allergy, angioedema; as an adjuvant in the treatment of anaphylactic reactions and serum sickness; pruritus from insect bites, eczema, dermatoses of allergic and non-allergic origin, in measles, rubella, chickenpox. Prophylactic hyposensitizing therapy in patients prone to allergic reactions.
For topical application: pruritic skin lesions in dermatoses, urticaria, insect bites, as well as in mild burns.
ICD codes
| ICD-10 code | Indication |
| B01 | Varicella [chickenpox] |
| B05 | Measles |
| B06 | Rubella [German measles] |
| J30.0 | Vasomotor rhinitis |
| J30.1 | Allergic rhinitis due to pollen |
| J30.3 | Other allergic rhinitis (perennial allergic rhinitis) |
| L20.8 | Other atopic dermatitis (neurodermatitis, eczema) |
| L23 | Allergic contact dermatitis |
| L24 | Irritant contact dermatitis |
| L28.0 | Lichen simplex chronicus (circumscribed neurodermatitis) |
| L29 | Pruritus |
| L30.0 | Nummular eczema |
| L50.9 | Urticaria, unspecified |
| T78.1 | Other adverse food reactions, not elsewhere classified |
| T78.3 | Angioneurotic edema (Quincke's edema) |
| T80.6 | Other serum reactions |
| T88.7 | Unspecified adverse effect of drug or medicament |
| ICD-11 code | Indication |
| 1E90.Z | Varicella, unspecified |
| 1F02 | Rubella |
| 1F03 | Measles |
| 4A85.21 | Urticaria or angioedema caused by food |
| 4A85.2Z | Food hypersensitivity, unspecified |
| 9A06.70 | Atopic eczema of the eyelids |
| CA08.00 | Allergic rhinitis due to pollen |
| CA08.03 | Other allergic rhinitis |
| CA08.3 | Vasomotor rhinitis |
| EA80.0 | Infantile atopic eczema |
| EA80.1 | Childhood atopic eczema |
| EA80.2 | Adult atopic eczema |
| EA80.Z | Atopic eczema, unspecified |
| EA82 | Nummular dermatitis |
| EA83.00 | Lichen simplex of vulva |
| EA83.01 | Lichen simplex of male genital organs |
| EA83.02 | Lichen simplex of perianal area |
| EA83.0Z | Lichen simplex of unspecified location |
| EA85.20 | Atopic hand eczema |
| EB04 | Idiopathic angioedema |
| EB05 | Hives, unspecified type |
| EC90.Z | Itching, unspecified |
| EK00.Z | Allergic contact dermatitis, unspecified |
| EK02.Z | Irritant contact dermatitis, unspecified |
| NE60 | Poisoning by drugs, medicaments or biological substances, not elsewhere classified |
| NE80.3 | Other serum reactions |
| NF09 | Adverse effects, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Gel, Drops
Orally. For adults and children over 12 years of age, the recommended daily dose is 3-6 mg, divided into 3 doses. For children aged from 1 month to 12 years, it is prescribed in a daily dose based on 0.1 mg/kg of body weight. The daily dose must be divided into 3 doses.
Topically. Apply to the affected area of skin 2-4 times/day.
In cases of severe itching or widespread skin lesions, simultaneous use of oral forms is recommended.
Adverse Reactions
From the immune system: with oral administration, very rarely – anaphylactoid reactions, including facial edema, pharyngeal edema, rash, muscle spasms, and shortness of breath.
From the nervous system with oral administration – fatigue, drowsiness (especially at the beginning of treatment), nervousness, excitement, muscle spasm; rarely – headache, dizziness, anxiety.
From the digestive system with oral administration, nausea, dry mouth or throat may occur.
Other with oral administration – edema; rarely – skin rash; in isolated cases – disorders of the respiratory system.
With topical application rarely – dryness and burning sensation at the application site, allergic skin reactions.
Contraindications
Hypersensitivity to dimetindene; angle-closure glaucoma, urination disorders (including with prostatic hyperplasia), children under 1 month of age (especially in case of premature birth).
For oral administration: bronchial asthma; first trimester of pregnancy; breastfeeding period.
Use in Pregnancy and Lactation
Oral administration. Dimetindene is contraindicated for oral administration in the first trimester of pregnancy. Use in the second and third trimesters of pregnancy is possible under medical supervision, only if the expected benefit to the mother outweighs the potential risk to the fetus. Use during breastfeeding is contraindicated.
Topical application. Use in the first trimester of pregnancy is possible only after consultation with a doctor. In the second and third trimesters of pregnancy, as well as during breastfeeding, it should not be applied to large areas of the skin, especially in the presence of inflammation or bleeding. Nursing mothers should not apply the product to the nipples of the mammary glands.
Pediatric Use
Oral administration. Contraindicated for use in children under 1 month of age (especially in case of premature birth). In children aged from 1 month to 1 year, the product should be used only as prescribed by a doctor and if there are indications for the use of H1-histamine receptor blockers, and exceeding the recommended doses should be avoided.
Topical application. In children from 1 month to 2 years, Dimetindene is used only after consultation with a doctor.
In infants and young children, the product should not be applied to large areas of the skin (especially with weeping and inflammation).
Geriatric Use
Use in elderly patients is permitted according to indications in recommended doses.
Special Precautions
Oral administration. In children aged from 1 month to 1 year, the product should be used only as prescribed by a doctor and if there are indications for the use of H1-histamine receptor blockers, and exceeding the recommended doses should be avoided.
Effect on ability to drive vehicles and machinery
During treatment, one should not engage in activities requiring increased attention and quick psychomotor reactions.
Topical application. In children from 1 month to 2 years, Dimetindene is used only after consultation with a doctor.
In infants and young children, the product should not be applied to large areas of the skin (especially with weeping and inflammation). In cases of severe itching or extensive skin lesions, Dimetindene should be used only after consultation with a doctor. When applying dimetindene topically to large areas of the skin, sun exposure should be avoided.
It is not effective for itching associated with cholestasis.
Drug Interactions
With simultaneous use with agents that have a depressant effect on the myocardium, it is possible to enhance the effect of the latter.
With simultaneous use with tricyclic antidepressants or anticholinergic agents, the risk of increased intraocular pressure increases.
MAO inhibitors may cause enhancement of the anticholinergic and sedative effects of dimetindene.
With simultaneous use, Dimetindene enhances the effect of anxiolytics, hypnotics.
With simultaneous consumption of ethanol, a slowing of reaction speed is observed.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Gel for external use 0.1%: tube 30 g
Marketing Authorization Holder
Erkapharm, JSC (Russia)
Manufactured By
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
| Allergolan | Gel for external use 0.1%: tube 30 g |
Dosage Form, Packaging, and Composition
Gel for external use homogeneous, colorless, transparent or slightly opalescent, practically odorless.
| 100 g | |
| Dimetindene maleate | 0.1 g |
Excipients: disodium edetate – 0.05 g, carbomer – 0.9 g, sodium hydroxide – 0.3 g, benzalkonium chloride – 0.005 g, propylene glycol – 15 g, purified water – up to 100 g.
30 g – aluminum tubes lacquered (1) – cardboard packs.
Oral drops 1 mg/ml: 20 ml bottle
Marketing Authorization Holder
Erkapharm, JSC (Russia)
Manufactured By
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
| Allergolan | Oral drops 1 mg/ml: 20 ml bottle |
Dosage Form, Packaging, and Composition
Oral drops in the form of a colorless, transparent liquid practically without odor.
| 1 ml | |
| Dimetindene maleate | 1 mg |
Excipients: sodium phosphate dibasic dodecahydrate – 16 mg, citric acid monohydrate – 5 mg, benzoic acid – 1 mg, disodium edetate – 1 mg, sodium saccharin – 0.5 mg, propylene glycol – 100 mg, purified water – up to 1 ml.
20 ml – dark glass bottles (1) with a dropper – cardboard packs.
